» Articles » PMID: 35770046

Delving the Role of : An Edible Wild Plant to Mitigate the Biomarkers of Metabolic Syndrome

Overview
Publisher Wiley
Date 2022 Jun 30
PMID 35770046
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic syndrome (MS), commonly known as syndrome X or insulin resistance syndrome, is a collection of risk factors for cardiovascular diseases and type II diabetes. MS is believed to impact over a billion individuals worldwide. It is a medical condition defined by visceral obesity, insulin resistance, high blood pressure, and abnormal cholesterol levels, according to the World Health Organization. The current dietary trends are more focused on the use of functional foods and nutraceuticals that are well known for their preventive and curative role against such pathological disorders. is one such medicinal plant that is gaining popularity. It is a wild, edible, succulent roadside shrub with cactus-like leaves. Besides its main nutrient contents, various bioactive constituents have been identified and linked with positive health outcomes of appetite-suppressing, hypolipidemic, antioxidant, hepatoprotective, and anticancer potentials. Hence, such properties make an invaluable plant against MS. The current review compiles recent available literature on nutritional composition, safety parameters, and therapeutic potential for MS. Summarized data in this review reveals that remains a neglected plant with limited food and therapeutic applications. Yet various studies explored here do prove its positive health-ameliorating outcomes.

Citing Articles

Cricket protein-based film containing Caralluma fimbriata extract-based nanoparticles for preservation of cheddar cheese.

Lone A, Bhat H, Kumar S, Ait-Kaddour A, Aadil R, Hassoun A Ultrason Sonochem. 2024; 112():107167.

PMID: 39616721 PMC: 11647646. DOI: 10.1016/j.ultsonch.2024.107167.


Medicinal Plant Extracts against Cardiometabolic Risk Factors Associated with Obesity: Molecular Mechanisms and Therapeutic Targets.

Gutierrez-Cuevas J, Lopez-Cifuentes D, Sandoval-Rodriguez A, Garcia-Banuelos J, Armendariz-Borunda J Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065815 PMC: 11280341. DOI: 10.3390/ph17070967.


Exploring the therapeutic potential of for antioxidant and diabetes management: a 28-day rat model study.

Arif A, Sultan M, Nazir F, Ahmad K, Kashif M, Ahmad M Toxicol Res (Camb). 2024; 13(4):tfae094.

PMID: 38957782 PMC: 11214972. DOI: 10.1093/toxres/tfae094.


Natural products target glycolysis in liver disease.

Li S, Hao L, Hu X Front Pharmacol. 2023; 14:1242955.

PMID: 37663261 PMC: 10469892. DOI: 10.3389/fphar.2023.1242955.


Encapsulation of Menthol and Luteolin Using Hydrocolloids as Wall Material to Formulate Instant Aromatic Beverages.

Mora-Florez L, Cabrera-Rodriguez D, Hernandez-Carrion M Foods. 2023; 12(10).

PMID: 37238898 PMC: 10217312. DOI: 10.3390/foods12102080.


References
1.
Fang J, Luncheon C, Patel A, Ayala C, Gillespie C, Greenlund K . Self-Reported Prevalence of Hypertension and Antihypertensive Medication Use Among Asian Americans: Behavioral Risk Factor Surveillance System 2013, 2015 and 2017. J Immigr Minor Health. 2020; 23(1):26-34. PMC: 10880142. DOI: 10.1007/s10903-020-01032-3. View

2.
Arora E, Khajuria V, Tandon V, Sharma A, Mahajan A, Gillani Z . To evaluate efficacy and safety of Caralluma fimbriata in overweight and obese patients: A randomized, single blinded, placebo control trial. Perspect Clin Res. 2015; 6(1):39-44. PMC: 4314845. DOI: 10.4103/2229-3485.148812. View

3.
McCracken E, Monaghan M, Sreenivasan S . Pathophysiology of the metabolic syndrome. Clin Dermatol. 2017; 36(1):14-20. DOI: 10.1016/j.clindermatol.2017.09.004. View

4.
Jayawardena R, Francis T, Abhayaratna S, Ranasinghe P . The use of Caralluma fimbriata as an appetite suppressant and weight loss supplement: a systematic review and meta-analysis of clinical trials. BMC Complement Med Ther. 2021; 21(1):279. PMC: 8579607. DOI: 10.1186/s12906-021-03450-8. View

5.
Zheng X, Chen T, Zhao A, Ning Z, Kuang J, Wang S . Hyocholic acid species as novel biomarkers for metabolic disorders. Nat Commun. 2021; 12(1):1487. PMC: 7935989. DOI: 10.1038/s41467-021-21744-w. View